TGTX

TG Therapeutics, Inc. (TGTX) - Q2 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Quarterly Report on Form 10-Q for the period ended June 30, 2026. TG Therapeutics is a commercial-stage biotechnology company focused on B-cell diseases. Its primary revenue driver is BRIUMVI (ublituximab-xiiy), approved for relapsing forms of multiple sclerosis (RMS). The company also holds rights to azer-cel (an allogeneic CAR T therapy) and is developing a subcutaneous formulation of ublituximab.

Key Financial Metrics (Six Months Ended June 30, 2026)

Note: Revenue includes $437.1 million in net product revenue (primarily U.S. sales of BRIUMVI) and $8.2 million in license/royalty revenue.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 70% year-over-year (from $262.0 million to $445.3 million), driven by expanded market penetration of BRIUMVI in the U.S. and sales to the ex-U.S. partner, Neuraxpharm.
• Profitability: The company reported net income of $27.6 million for the six-month period, compared to $33.2 million in the prior year period. Operating income improved to $56.5 million from $43.5 million.
• Debt Restructuring: In March 2026, the company refinanced its initial $250 million term loan with a new $750 million term loan (2026 Term Loan) with Blue Owl Capital, maturing in 2031. This resulted in a $9.2 million loss on extinguishment of debt recorded in the first half of 2026.
• Expense Increases: Research and Development (R&D) expenses rose to $143.7 million (from $78.1 million) due to subcutaneous development and clinical trials. Selling, General, and Administrative (SG&A) expenses increased to $170.3 million (from $105.9 million) due to commercialization scaling and stock-based compensation.
• Share Repurchases: The company repurchased approximately $100 million of its common stock under its 2025 Share Repurchase Program during the period.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Liquidity: Management states that existing cash, investments, and projected revenues are sufficient to fund operations for more than 12 months. No immediate need for additional capital is anticipated.
• Pipeline Progress:
  • ENHANCE Trial: Positive topline results announced in May 2026 for a consolidated single infusion regimen for BRIUMVI initiation.
  • Subcutaneous BRIUMVI: Positive Phase 1 data announced in June 2026; Phase 3 top-line data expected late 2026 or Q1 2027.
  • New Indications: Phase 2 trials initiated for BRIUMVI in Myasthenia Gravis and treatment-resistant schizophrenia.

Key Risks & Contingencies:

• Regulatory & Commercialization: Risks related to maintaining FDA approval, achieving broad market acceptance, and potential pricing pressures from government regulations (e.g., Inflation Reduction Act, MFN pricing).
• Debt Obligations: The $750 million loan is secured by substantially all assets and includes covenants that could restrict operations if breached.
• Third-Party Dependence: Reliance on third-party manufacturers (e.g., Samsung Biologics) for commercial supply and CROs for clinical trials.
• Intellectual Property: Risks regarding patent challenges and the ability to enforce IP rights globally.

Investor Verification Checklist

• Verify the sustainability of the 87% gross margin on U.S. net product revenue as sales volume scales and royalty obligations increase.
• Monitor the interest expense trajectory associated with the new $750 million term loan and its impact on future net income.
• Confirm the timeline and data readout for the Phase 3 subcutaneous BRIUMVI trial, which is critical for future market expansion.
• Review the stock-based compensation expense trends, which significantly impacted SG&A and R&D in the current period.
• Assess the accounts receivable aging and collection trends given the extended payment terms offered to customers during the commercial launch.